Immunai Raises $215 Million in Series B Funding
- Immunai, a New York-based biotech company, raised $215M in Series B funding, increasing the company’s total funding to date to $295M
- The Series B was led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, and more
- The company intends to use the funds to expand its “drug actuary” platform for target validation and evaluation
- The company uses single-cell genomics and machine learning to discover and develop novel therapeutics that reprogram the immune system
- In conjunction with the funding, Eli Groner, Managing Director at Koch Disruptive Technologies, will be joining the company’s board of directors
